Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Clin Transl Oncol ; 25(1): 151-159, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-35986133

RESUMO

BACKGROUND: Adherence to clinical practice guidelines improves outcomes for patients with breast cancer. However, their implementation may not be feasible in low- and middle-income countries. This study aimed to evaluate physicians' adherence, attitudes, and barriers towards the Colima Consensus, which is the Mexican national breast cancer clinical practice guideline. METHODS: A cross-sectional, 31-item survey was e-mailed to Consensus attendees and members of the Mexican Society of Oncology and Mexican Mastology Association. Descriptive statistics, univariate, and multivariate analysis were used to analyze the associations between participants' characteristics, adherence, attitudes, and barriers. RESULTS: Of 439 respondents, 78% percent adhered to Consensus recommendations and 94% believed it was applicable to their clinical practice. Forty percent reported using the Consensus as their sole breast cancer guideline. This was associated with being a surgical oncologist (OR 3.3, 95% CI 2.0-5.3) and practicing at a public hospital (OR 2.1, 95% CI 1.2-3.7). The most common barriers to adherence were lack of resources and logistical problems. Regarding attitudes towards the Consensus, 90% considered it a good educational tool, 89% considered it a reliable source of information, and 90% thought it improved quality of care. CONCLUSIONS: We showed high levels of adherence and positive attitudes towards the Colima Consensus, with a significant proportion of physicians using it as their only guideline. Lack of resources and logistical issues were the main barriers to adherence. Our results highlight the relevance of local breast cancer guidelines and suggest a need for the creation of resource-stratified guidelines.


Assuntos
Neoplasias da Mama , Médicos , Humanos , Feminino , Neoplasias da Mama/terapia , Estudos Transversais , México , Atitude do Pessoal de Saúde , Fidelidade a Diretrizes , Padrões de Prática Médica , Inquéritos e Questionários
2.
Rep Pract Oncol Radiother ; 27(5): 914-926, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36523808

RESUMO

Background: Radiotherapy (RT) is an essential element in cancer treatment: 50-70% of cancer patients receive RT at some time of the course of their disease. Of these, almost 95% experience some grade of radiation dermatitis (RD). RD can affect patient's quality of life during and after treatment. Consequently, the management of RD is important. There are few randomized controlled clinical trials on interventions used to prevent and treat RD and no standardized consensus on RD management. A panel of opinion leaders of the Mexican Society of Radiotherapy (SOMERA) took part in a study of oncologic practice in Mexico. The following clinical guide is referenced both by the national practice reality and international evidence. Materials and methods: This RD management guide is based on input provided by 25 Mexican radiation oncologists, whose criteria were gathered using the Delphi Method and article review. Results: Twenty-one questions about experience in RD treatment were voted. More than 80% of the panel agreed with: the use of dermocosmetics/medical device in prevention and in treatment of RD grades 1-2. As for grade 3, they recommend individualizing each case and dermatologist evaluation. Topical steroids should be used when there is skin itching or pain. Consider the use of natural soaking elements. Skin care must be continued to avoid or reduce severity of late radiation skin lesions. Conclusion: This consensus was developed as a supportive educational tool that can be adapted to individual clinical needs, useful for professionals involved in the treatment of RT patients.

3.
Rep Pract Oncol Radiother ; 23(6): 533-539, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30534017

RESUMO

In recent years, the treatment of locally-advanced and metastatic cervical cancer has improved greatly due to the introduction of targeted therapies, new chemotherapy combinations, and emerging treatments. Candidates for potentially curative treatment are those patients with good functional status without associated comorbidities. Numerous trials have demonstrated that chemotherapy prolongs survival versus supportive care alone. In addition, polychemotherapy schemes are superior to single agent regimens. Targeted molecular agents have proven beneficial in the treatment of cervical cancer. Second-line treatment should be considered standard practice in patients with good functional status. Finally, given the poor survival outcomes in patients with metastatic disease, participation in clinical studies should always be considered the best option.

4.
Rep Pract Oncol Radiother ; 23(6): 540-546, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30534018

RESUMO

The current standard of care for locally advanced cervical cancer is whole pelvis and para-aortic radiation when indicated, delivered concomitantly with chemotherapy and brachytherapy. Para-aortic node involvement is a predictor of survival in locally advanced disease but presence of metastases is difficult to determine because the currently available imaging methods lack enough sensitivity to be able to detect accurately para-aortic metastases when surgical staging is not feasible. The objective of this review is to describe the current status of para-aortic lymph node irradiation in locally advanced cervical cancer. It includes analysis of the diagnostic imaging and surgical approaches for assessment of para-aortic lymph node dissemination, together with indications for radiotherapy and radiotherapeutic techniques.

5.
Rep Pract Oncol Radiother ; 23(2): 91-96, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29681771

RESUMO

AIM: To evaluate the dose distribution to the left anterior descending (LAD) coronary artery in patients treated with postoperative three-dimensional conformal radiotherapy (3DCRT). BACKGROUND: Postoperative radiotherapy may increase the risk of heart disease, particularly in patients with left-sided breast cancer. Clinical data on doses to the LAD are limited. MATERIALS AND METHODS: Retrospective study of 14 patients who underwent postoperative 3DCRT for left breast cancer in 2014. All data were retrieved from medical records. Means, medians, ranges, and percentages were calculated. RESULTS: The mean dose to the LAD in patients with V25 < 1% was 0.12 cGy. Dmean, Dmax and V25 to the heart were, respectively, 3.7 Gy (range, 0.9-4.18), 40.3 Gy (9.28-62.9), and 1.59 cGy. The mean Dmean and Dmax values in the sample were 9.71 Gy and 33.2 Gy, respectively. The maximum dose to the LAD (D2%) ranged from 3.66 to 53.01 Gy. Due to the spacing of the CT slices (5 mm), it was not possible to completely contour the entire artery. The mean dose to the heart (3.3 Gy) was considered acceptable. CONCLUSIONS: The maximum dose to the LAD was as high as 53 Gy, suggesting an increased risk of cardiac morbidity. This study underscores the value of contouring the LAD and the value of the breath hold technique to reduce maximum cardiac doses. Smaller CT cuts (2.5 mm) can improve contouring. Larger studies with long-term follow up are needed to determine the radiation tolerance dose for the LAD.

6.
Arch Med Res ; 45(3): 229-36, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24606815

RESUMO

BACKGROUND AND AIMS: Although the latent membrane protein type 1 (LMP1) is frequently expressed in Epstein-Barr virus (EBV) malignancies, its contribution to the pathogenesis of nasopharyngeal carcinoma (NPC) is not fully defined. LMP1 functions as a viral mimic of the TNFR family member engaging a number of signaling pathways that induce morphological and phenotypic alterations. This study aimed to investigate the LMP1 expression and EBV infection in relation to clinical outcome and survival in a series of Mexican NPC patients. We also studied expression of p16 and p53 proteins. METHODS: We analyzed in 25 tumor specimens the expression of LMP1, p16 and p53 by immunohistochemistry (IHC) and EBV presence by IHC/in situ hybridization. Differences in clinical outcome and survival in relation to protein expression were correlated through χ(2) statistics and Kaplan-Meier survival curves. RESULTS: Our results showed a rate of 92% (23/25) of EBV infection. The expressions of LMP-1, p16 and p53 proteins were 40.0, 44.0 and 40.0%, respectively. LMP-1 immunoexpression was more common in older patients (>50 vs. <50 years old, p = 0.02) and with parapharyngeal space invasion (p = 0.02). The presence of metastatic disease at diagnosis (p = 0.03), distant recurrence disease (p = 0.006) and shorter distance recurrence-free survival (p = 0.05) was associated with lack of p16. CONCLUSIONS: In our series, EBV infection rates are particularly high for nonendemic NPC, although without a statistically significant difference in overall survival, LMP1 and p16 expression was correlated with poorer clinical prognosis. Probably, LMP1 and p16 detection identify a worse clinical prognosis in NPC patient subgroup.


Assuntos
Carcinoma/metabolismo , Inibidor p16 de Quinase Dependente de Ciclina/metabolismo , Infecções por Vírus Epstein-Barr/metabolismo , Herpesvirus Humano 4/genética , Neoplasias Nasofaríngeas/metabolismo , Proteína Supressora de Tumor p53/metabolismo , Proteínas da Matriz Viral/metabolismo , Adulto , Idoso , Carcinoma/patologia , Infecções por Vírus Epstein-Barr/patologia , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Carcinoma Nasofaríngeo , Neoplasias Nasofaríngeas/patologia , Recidiva Local de Neoplasia , Estudos Retrospectivos , Fatores Sexuais , Proteínas da Matriz Viral/genética , Adulto Jovem
7.
Rep Pract Oncol Radiother ; 18(2): 57-60, 2012 Oct 04.
Artigo em Inglês | MEDLINE | ID: mdl-24416531

RESUMO

AIM: This survey is performed to learn about the structure of radiotherapy in México. BACKGROUND: Radiation oncology practice is increasing because of the higher incidence of cancer. There is no published data about radiotherapy in México. MATERIALS AND METHODS: A questionnaire was sent to the 83 registered centers in the database of the Mexican regulatory agency. One out of the 32 states has no radiotherapy. 27 centers from 14 states provided their answers. RESULTS: 829 patients are treated annually with any radiotherapy modality in each center. Two centers have one cobalt machine, 7 have a cobalt and a linac and 10 have more than one linac. Five centers use 2D planning systems, 22 use 3D; 9, conventional simulators; 22, CT based simulation, and 1 center has no simulation. Most of the centers verify beams with films, electronic portal image devices and cone beam CTs are also used. Intensity modulated and image guided radiotherapy are performed in 5 states. Breast, prostate, cervix, lung, rectum and head and neck cancer are the six most common locations. There are 45 public and 38 private centers, 2 dedicated to children. Two gamma knife units, 5 Novalis systems, 1 tomotherapy and 2 cyberknife machines are working. All centers have at least one radiation oncologist, one physicist and one radiotherapist. CONCLUSIONS: Definitive conclusions cannot be drawn from this limited feedback due to a low participation of centers. This survey about radiotherapy in Mexico shows the heterogeneity of equipment as well as medical and technical staff in the whole country.

8.
J Contemp Brachytherapy ; 1(4): 237-239, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28050178

RESUMO

PURPOSE: To report the results of the Instituto Nacional de Cancerología México, of low dose rate brachytherapy for cervical cancer using only a tandem. A proportion of patients was treated with only a tandem, without ovoids, due to the distorted anatomy because of the tumour or previous external radiation, or sometimes due to physician preference. MATERIAL AND METHODS: We report the results of 120 patients treated only with a tandem and the impact of this treatment on local control and survival from January 2005 to December 2006. The frequency of FIGO stage was: IIB 47%, IIIB 34%, IIA 9%, IIIA 4%, IB2 3% and IB1 3%. The median overall treatment time was 12 weeks. The value of the external beam radiation dose was 50-50.4 Gy in all patients and the value of the brachytherapy dose was 30 Gy given to point A. RESULTS: Complete clinical response was 83% at the end of brachytherapy. Time to recurrence and frequency were: IB1 - 17 months (20%), IB2 - none, IIA - 8 months (8.3%), IIB - 11 months (40%) and IIIB - 14 months (25%). 10.8% of patients had a persistent tumour, 3.3% had progression during treatment in stage IIB. Survival in months was 26 months for stage IB1, 30 for IB2, 25 for IIA, 28 for IIB, 27 for IIIA and 24 for IIIB. 25% of patients died during follow-up. CONCLUSIONS: These preliminary results suggest that there is no significant difference between the treatment with brachytherapy using a tandem and ovoids or a tandem alone.

9.
Int Wound J ; 5(2): 246-57, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18494630

RESUMO

Ulcers in radiated skin continue to be a challenge for health care practitioners. Healing impairment in the setting of radiation-damaged tissue will most of the time lead to chronic wounds that reduce the patient's quality of life. In this review, we present an update of the pathophysiology of tissue damage caused by radiation that leads to chronic ulceration. We also explore the evidence available on the different prevention and treatment modalities that have been reported in the literature. The evidence for most preventive measures is inconclusive; however, sucralfate and amifostine seem to be the adequate recommendations for prophylaxis. As for treatment of ulcerated patients, the strongest level of evidence found was for the use of pentoxifylline, but proper trials are still scarce to be considered standard adjuvant therapy. Hyperbaric oxygen, cytokines and other growth factors and surgical interventions have shown some benefit in case reports and case series only. Other therapies show promise based on their mechanism of action but need to be tested in human studies and clinical trials.


Assuntos
Lesões por Radiação/fisiopatologia , Lesões por Radiação/terapia , Úlcera Cutânea/fisiopatologia , Úlcera Cutânea/terapia , Cicatrização/fisiologia , Humanos , Lesões por Radiação/diagnóstico , Radioterapia/efeitos adversos , Úlcera Cutânea/etiologia
10.
Breast Cancer Res Treat ; 95(2): 147-52, 2006 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-16319989

RESUMO

BACKGROUND: Nearly 60% of breast cancer cases in Mexico are in advanced stages. At our institution, concomitant preoperative chemoradiation is being used in patients with advanced breast cancer. In the present study, we evaluated the postoperative wound complications and risk factors associated. PATIENTS AND METHODS: The study included breast cancer patients from January 2000 to December 2002 treated with concomitant preoperative chemoradiation and mastectomy. Wound complication rates were described along with a nested case-control analysis to evaluate risk factors for postoperative major wound complications. RESULTS: We evaluated 360 patients treated with preoperative chemoradiation. About 165 patients (45.8%) developed a wound complication (infection and/or flap necrosis); 60 (16.6%) patients had a surgical site infection (SSI) and 61 (16.9%), flap necrosis; 44 (12.2%) developed both complications, and 25 (6.9%) experienced late dehiscence after suture removal. Epidermolysis, seroma, and hematoma occurred in 93 (25.8%), 80 (22.2%), and 12 patients (3.3%), respectively. Case-control analysis was conducted in 335 patients. After logistic regression analysis, the sole variable found associated with SSI and/or flap necrosis was epidermolysis (OR = 8.81, 95% CI = 4.52-17.18). Although not significant and of lesser magnitude, adjusted risk estimates of overweight, age >50 years, and type of mastectomy showed the same trend. CONCLUSIONS: Postoperative wound complications were not different from those observed in non-radiated patients, but its rate was higher. Epidermolysis was associated with SSI and/or flap necrosis. Careful surgical technique should be encouraged.


Assuntos
Neoplasias da Mama/cirurgia , Mastectomia/efeitos adversos , Complicações Pós-Operatórias , Dermatopatias/etiologia , Cicatrização , Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/radioterapia , Estudos de Casos e Controles , Quimioterapia Adjuvante , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Necrose , Radioterapia Adjuvante , Fatores de Risco , Retalhos Cirúrgicos
11.
Oral Oncol ; 42(2): 172-6, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16246617

RESUMO

Osteosarcoma is an infrequent, locally aggressive neoplasm in the head and neck region. To date, surgery is the mainstay of treatment. However, patients with mandibular osteosarcomas usually have a locally advanced disease at diagnosis and therefore represent a therapeutic challenge because surgical margins are difficult to obtain due to aesthetic and functional concerns. To evaluate possible prognostic factors implicated in recurrence, persistence or relapse in osteosarcoma of the mandible, with special reference to the soft tissue and bone surgical margins. A series of 20 patients with mandibular osteosarcomas treated at the Instituto Nacional de Cancerología (México) from 1985 to 1999 are reviewed. There were 14 female and 6 male patients. Twelve cases were treated with surgery alone, 3 patients with surgery and adjuvant radiotherapy, 1 had neoadjuvant chemotherapy followed by surgery, 1 had neoadjuvant chemotherapy, surgery and postoperative radiotherapy, 1 with surgery and adjuvant chemotherapy, 1 with surgery followed by adjuvant chemotherapy and radiotherapy and one patient rejected treatment. Between 1985 and 1992 these neoplasms were treated by means of total mandibulectomy, independently of tumor size, but between 1993 and 1999 the policy was to practice smaller resections but long enough to obtain macroscopic surgical free margins. In the first period the relationship between mandibular size resection and tumor size was 1.9, meanwhile in the second period the relation was 1.5. There was not significant difference between both periods in terms of tumor size (6.0 cm vs. 6.02 cm at the time of surgery) nor in local control and survival. Soft tissue involvement as reported by histological study was strongly associated with recurrence (p = 0.0024). Overall 5-year survival was 20%. A policy of total mandibulectomy is not associated with a better local control or survival. Extent of resection must be tailored with tumor size. Extent of margins in soft tissue is the limiting factor for local control.


Assuntos
Neoplasias Mandibulares/cirurgia , Osteossarcoma/cirurgia , Adolescente , Adulto , Idoso , Quimioterapia Adjuvante , Feminino , Humanos , Masculino , Neoplasias Mandibulares/patologia , Neoplasias Mandibulares/terapia , Pessoa de Meia-Idade , Terapia Neoadjuvante , Invasividade Neoplásica , Recidiva Local de Neoplasia , Osteossarcoma/patologia , Osteossarcoma/terapia , Prognóstico , Radioterapia Adjuvante , Análise de Sobrevida , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...